The announcement of positive trial results typically leads to increased investor optimism about a company's future prospects, especially when it concerns a treatment for a condition with high unmet medical needs like CF. The involvement of key opinion leaders in the event adds credibility to the findings, and the FDA's Fast Track designation suggests a smoother regulatory path ahead, potentially accelerating the treatment's time to market. These factors combined are likely to have a positive short-term impact on BiomX's stock price.